Autologous Myogenic Stem Cell Therapy (Maastricht University)

N/A

Report date: 2023/08/03 09:25:59

Base Information

Drug NameAutologous Myogenic Stem Cell Therapy (Maastricht University)
Drug Alias NameAutologous MesoangioblastsAutologous MABsAutologous Mesoangioblast AdministrationMABs AdministrationMABs Therapy
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Mesoangioblasts therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsMitochondrial Myopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMaastricht University Medical Centre
China Registration ClassN/A

Develop Information

Active CompaniesMaastricht UniversityMaastricht University Medical Centre
Inactive CompaniesN/A
Active IndicationsMitochondrial Myopathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A